pp-027 Vials, injection
Dossier type
CTD
Dossier status
Under development
Country of origin
South Korea
Comments
Indication: 6-in-1 combination vaccine for infants to prevent: diphtheria (D), tetanus (T), whole-cell pertussis (wP), hepatitis B (HepB), Haemophilus influenzae type b (Hib), and inactivated poliovirus (IPV), Phase II development. Combination pediatric vaccine (hexavalent) combining six antigens in one formulation — potential to reduce number of injections and improve uptake. Planned for global supply readiness. Injectable vaccine
Manufacturer #16907
This South Korea–based life-sciences organization develops a portfolio of small-molecule and biologic therapeutics, with a strategic focus on oncology, immunology, and metabolic diseases. Its pharmaceutical R&D is supported by global clinical programs and collaborations aimed at advancing first-in-class and best-in-class candidates. The group also maintains established therapeutic franchises and leverages international partnerships to expand its presence in the global healthcare market.
Manufacturer usually replies in 53 days